Syngene International Ltd
Company Profile
Business description
Syngene International Ltd is a contract research, development and manufacturing organization (CRDMO) providing integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. Its business divisions include Discovery Services, Translational & Clinical Research, Dedicated Centers, and Contract Development and Manufacturing Services. Its services cover lead generation, medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development, and clinical development services. The Company operates in a single segment of contract research and manufacturing services, with the majority of its revenue derived from the USA.
Contact
Electronic City, Phase 1
The Hub, Tower 8A, 360 Degree Business Park
Doddathoguru
BengaluruKA560100
INDT: +91 8068919191
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
7,210
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,338.81 | 39.05 | -0.47% |
| DAX 40 | 24,830.98 | 84.51 | -0.34% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,600.37 | 28.13 | 0.27% |
| HKSE | 24,562.24 | 446.36 | -1.78% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.15 | 118.26 | -3.05% |